AstraZeneca Pharma receives GST order of Rs 9.24 crore for FY 2018-19

2 min read Updated on 05 Jun 2026, 02:33 AM

Reviewed by

Suketu GScanX News Team

AI Summary

AstraZeneca Pharma India Limited received an order from the Deputy Commissioner of State Tax (Appeal) for FY 2018-19 involving claims of Rs 9.24 crore. The order, passed under section 107 of the Maharashtra Goods and Services Act, 2017, upholds adjustments related to supplies under the Patient Access Program. The company intends to challenge the order before the GST Appellate Tribunal.

*this image is generated using AI for illustrative purposes only.

AstraZeneca Pharma India Limited received an order from the Deputy Commissioner of State Tax (Appeal) for FY 2018-19 involving claims of Rs 9.24 crore, impacting its financial position regarding tax liabilities. The order, passed under section 107 of the Maharashtra Goods and Services Act, 2017, upholds certain adjustments initially made by the Assistant Commissioner of State Tax Investigation. These adjustments relate to supplies made by the company under its Patient Access Program.

The order is a development in an appeal filed by the company on June 29, 2020, against the original order issued by the Assistant Commissioner of State Tax Investigation. This prior order was intimated to the stock exchanges on August 14, 2023. The company stated that the matter will be suitably challenged in due course by filing an appeal before the GST Appellate Tribunal (GSTAT).

The expected overall financial implication cannot be determined at this stage, as the matter is subject to further legal proceedings. The quantum of claims stands at Rs 9.24 crore, excluding interest and penalty. The company has not yet quantified the potential impact of interest or penalties that may arise from the order.

Details of the dispute

The following table outlines the key details of the litigation and the order received:

Sl. No.	Particulars	Details
1.	Name of the opposing party	Deputy Commissioner of State Tax (Appeal)
2.	Brief details of dispute/litigation	Company has received an appeal order for the financial year 2018-19, wherein certain adjustments initially made by the Assistant Commissioner of State Tax Investigation relating to supplies made by the Company under Patient Access Program, have been upheld by the Deputy Commissioner of State Tax (Appeal).
3.	Court/tribunal/agency where the litigation is filed	The order was passed by the Deputy Commissioner of State Tax (Appeal). The matter will be challenged before the GST Appellate Tribunal (GSTAT) by filing an appeal.
4.	Expected financial implications, if any, due to compensation, penalty etc.	Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 9.24 crores (approx.) excluding interest and penalty.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on behalf of AstraZeneca Pharma India Limited.

Historical Stock Returns for AstraZeneca Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.50%	-1.54%	+3.67%	-6.62%	-8.80%	+126.16%

What is the expected timeline for AstraZeneca Pharma India to file an appeal before the GST Appellate Tribunal (GSTAT)?

How might this tax dispute impact AstraZeneca's future Patient Access Program initiatives or similar corporate social responsibility activities?

Could this ruling set a precedent for other pharmaceutical companies facing similar GST scrutiny regarding patient assistance programs?

Read Next Article

AstraZeneca Pharma India surrenders factory license

1 min read Updated on 04 Jun 2026, 04:13 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

AstraZeneca Pharma India Limited surrendered its factory license to the Department of Factories, Boilers, Industrial Safety and Health on June 3, 2026. The license, valid from December 14, 2023, to December 31, 2026, was surrendered for cancellation by an Administrative Committee of the Board of Directors. The company confirmed that the license was surrendered voluntarily and not withdrawn or suspended by the regulatory authority.

*this image is generated using AI for illustrative purposes only.

AstraZeneca Pharma India Limited surrendered its factory license to the Department of Factories, Boilers, Industrial Safety and Health on June 3, 2026. The license, valid from December 14, 2023, to December 31, 2026, was surrendered for cancellation by an Administrative Committee of the Board of Directors. This move follows the company's earlier intimations to the stock exchanges regarding the exit from its manufacturing site and the surrender of the manufacturing license.

The approval to surrender the license was granted by the Administrative Committee of the Board of Directors. The company had previously informed the exchanges about its decision to exit the manufacturing site on June 21, 2024, and about the surrender of the manufacturing license on September 2, 2025.

The details of the surrendered license were submitted in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that the license was surrendered voluntarily and not withdrawn or suspended by the regulatory authority.

The table below summarizes the key details of the license surrender:

Sl. No.	Particulars	Details
1	Name of the regulatory or licensing authority	Department of Factories, Boilers, Industrial Safety and Health.
2	Brief details of the approval/license obtained/ withdrawn/ surrendered	The Company has surrendered its factory license, which was valid up to December 31, 2026, to the Department of Factories, Boilers, Industrial Safety and Health for cancellation.
3	Impact/relevance of such approval/license to the listed entity	Not applicable
4	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not applicable
5	Period for which such approval/license is/was valid	The license is valid for a period from December 14, 2023 to December 31, 2026.
6	Actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not applicable

The intimation was submitted by Tanya Sanish, Company Secretary & Compliance Officer of AstraZeneca Pharma India Limited. The company requested the stock exchanges to take the intimation on record.

Historical Stock Returns for AstraZeneca Pharma